Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases

  • Ezogelin Oflazoglu
  • Iqbal S. Grewal
  • Hanspeter Gerber
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 647)


The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin’s disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin’s lymphomas (NHLs). Increased CD30L expression was found on mast cells within HD tumors and preclinical and clinical studies with compounds targeting the CD30/ CD30L system in HD and ALCL demonstrated therapeutic benefit. Upregulation of CD30 and CD30L is also linked to leukocytes in patients with chronic inflammatory diseases, including lupus erythematosus, asthma, rheumatoid arthritis and atopic dermatitis (AD). Preclinical studies conducted with transgenic mice or biologic compounds suggested important regulatory functions of the CD30-CD30L system in various aspects of the immune system. Such key regulatory roles and their low expression in normal conditions combined with increased expression in malignant tissues provided a strong rationale to investigate CD30 and CD30L as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases. In this report, we review the pharmacodynamic effects of specific therapeutic compounds targeting the CD30/CD30L system in preclinical- and clinical studies.


Atopic Dermatitis CD30 Ligand Anaplastic Large Cell Lymphoma Soluble CD30 Antibody Drug Conjugate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smith CA et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73(7):1349–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Gruss H J, Duyster J, Herrmann. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin’s disease. Ann Oncol 1996; 7 Suppl 4:19–26.PubMedGoogle Scholar
  3. 3.
    Durkop H et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 1992; 68(3):421–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Cabanillas F et al. Lymphomatoid papulosis: a T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med 1995; 122(3):210–7.PubMedGoogle Scholar
  5. 5.
    Berro AI, Perry GA, Agrawal DK. Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol 2004; 173(3):2174–83.PubMedGoogle Scholar
  6. 6.
    Agrawal B, Reddish M, Longenecker BM. CD30 expression on human CD8+ T-cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996; 157(8):3229–34.PubMedGoogle Scholar
  7. 7.
    Romagnani S et al. Role for CD30 in HIV expression. Immunol Lett 1996; 51(1–2):83–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Durkop H et al. Expression of the CD30 antigen in nonlymphoid tissues and cells. J Pathol 2000; 190(5):613–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaudewitz P et al. Atypical cells in lymphomatoid papulosis express the Hodgkin cell-associated antigen Ki-1. J Invest Dermatol 1986; 86(4):350–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Chiarle R et al. CD30 in normal and neoplastic cells. Clin Immunol 1999; 90(2):157–64.PubMedCrossRefGoogle Scholar
  11. 11.
    Granados S, Hwang ST. Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases. J Invest Dermatol 2004; 122(6):345–7.CrossRefGoogle Scholar
  12. 12.
    Stein H et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000; 96(12):3681–95.PubMedGoogle Scholar
  13. 13.
    Younes A, ME Kadin. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21(18):3526–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Zinzani PL et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 1996; 14(3):955–62.PubMedGoogle Scholar
  15. 15.
    Pizzolo G, Romagnani S. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma. Haematologica 1995; 80(4):357–66.PubMedGoogle Scholar
  16. 16.
    Iyn H et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol 2000; 27(3):698–702.Google Scholar
  17. 17.
    McMillan SA et al. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. Acta Neurol Scand 2000; 101(4):239–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Horn-Lohrens O et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995; 60(4):539–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Nadali G et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin’s disease at high risk of unfavorable outcome. Blood 1998; 91(8):3011–6.PubMedGoogle Scholar
  20. 20.
    Pizzolo G et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin’s disease: relationship with disease activity and clinical stage. Br J Haematol 1990; 75(2):282–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Pizzolo G et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997; 108(2):251–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Caligaris-Cappio F et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995; 13(3):339–43.PubMedGoogle Scholar
  23. 23.
    Gerli R et al. High levels of the soluble form of CD30 mole cule in rheumatoid arthritis (RA) are expression of CD30+ T-cell involvement in the inflamed joints. Clin Exp Immunol 1995; 102(3):547–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Okumura M et al. Increased serum concentration of soluble CD30 in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 1997; 82(6):1757–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Bengtsson A et al. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clin Exp Immunol 1997; 109(3):533–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Dummer W, Brocker EB, Bastian BC. Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis. Br J Dermatol 1997; 137(2):185–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Caproni M et al. In vivo relevance of CD30 in atopic dermatitis. Allergy 1997; 52(11):1063–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Frezzolini A et al. Soluble CD30 in pediatric patients with atopic dermatitis. Allergy 1997; 52(1):106–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Heshmat NM, El-Hadidi ES. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Pediatr Allergy Immunol 2006; 17(4):297–303.PubMedCrossRefGoogle Scholar
  30. 30.
    Leonard C et al. Allergen-induced CD30 expression on T-cells of atopic asthmatics. Clin Exp Allergy 1997; 27(7):780–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Nogueira JM et al. Soluble CD30, dehydroepiandrosterone sulfate and dehydroepiandrosterone in atopic and non-atopic children. Allerg Immunol (Paris) 1998; 30(1):3–8.Google Scholar
  32. 32.
    Croager EJ, Abraham LJ. Characterisation of the human CD30 ligand gene structure. Biochim Biophys Acta 1997; 1353(3):231–5.PubMedGoogle Scholar
  33. 33.
    Gattei V et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89(6):2048–59.PubMedGoogle Scholar
  34. 34.
    Gruss HJ et al. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83(8):2045–56.PubMedGoogle Scholar
  35. 35.
    Gruss HJ et al. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 1994; 8(12):2083–94.PubMedGoogle Scholar
  36. 36.
    Nicod LP, Isler P. Alveolar macrophages in sarcoidosis coexpress high levels of CD86 (B7.2), CD40 and CD30L. Am J Respir Cell Mol Biol 1997; 17(1):91–6.PubMedGoogle Scholar
  37. 37.
    Pinto A et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin’s disease cell line. Blood 1996; 88(9):3299–305.PubMedGoogle Scholar
  38. 38.
    Shanebeck KD et al. Regulation of murine B-cell growth and differentiation by CD30 ligand. Eur J Immunol 1995; 25(8):2147–53.PubMedCrossRefGoogle Scholar
  39. 39.
    Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol 1996; 157(8):3635–9.PubMedGoogle Scholar
  40. 40.
    Younes A et al. CD30 ligand is expressed on resting normal and malignant human B-lymphocytes. Br J Haematol 1996; 93(3):569–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Molin D et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin’s disease. Br J Haematol 2001; 114(3):616–23.PubMedCrossRefGoogle Scholar
  42. 42.
    Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997; 11(21):2810–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Aizawa S et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997; 272(4):2042–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Duckett CS et al. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997; 17(3):1535–42.PubMedGoogle Scholar
  45. 45.
    Horie R et al. A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation. Int Immunol 1998; 10(2):203–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000; 96(13):4307–12.PubMedGoogle Scholar
  47. 47.
    Boll B et al. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005; 106(5):1839–42.PubMedCrossRefGoogle Scholar
  48. 48.
    Chiarle R et al. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999; 163(1):194–205.PubMedGoogle Scholar
  49. 49.
    Gilfillan MC et al. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998; 160(5):2180–7.PubMedGoogle Scholar
  50. 50.
    Podack ER et al. CD30-governor of memory T-cells? Ann N Y Acad Sci 2002; 975:101–13.PubMedCrossRefGoogle Scholar
  51. 51.
    Gaspal FM et al. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T-cell memory. J Immunol 2005; 174(7):3891–6.PubMedGoogle Scholar
  52. 52.
    Fischer M et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006; 116(10):2748–56.PubMedCrossRefGoogle Scholar
  53. 53.
    Schneider C, Hubinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002; 43(7):1355–66.PubMedCrossRefGoogle Scholar
  54. 54.
    Hsu PL, Hsu SM. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin’s disease and anaplastic large cell lymphoma. Lab Invest 2000; 80(7):1111–9.PubMedGoogle Scholar
  55. 55.
    Tian ZG et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 1995; 55(22):5335–41.PubMedGoogle Scholar
  56. 56.
    Pfeifer W et al. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am J Pathol 1999; 155(4):1353–9.PubMedGoogle Scholar
  57. 57.
    Wahl AF et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res 2002; 62(13):3736–42.PubMedGoogle Scholar
  58. 58.
    Cerveny, CG et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin’s disease cells to conventional chemotherapeutics. Leukemia 2005; 19(9):1648–55.PubMedCrossRefGoogle Scholar
  59. 59.
    Klimka A et al. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA’) is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer 1999; 80(8):1214–22.PubMedCrossRefGoogle Scholar
  60. 60.
    Pasqualucci L et al. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood 1995; 85(8):2139–46.PubMedGoogle Scholar
  61. 61.
    Falini B et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339(8803):1195–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Hamblett KJ et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004; 10(20):7063–70.PubMedCrossRefGoogle Scholar
  63. 63.
    Francisco JA et al. AC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102(4):1458–65.PubMedCrossRefGoogle Scholar
  64. 64.
    Falini B et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin’s disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol 1992; 82(1):38–45.PubMedCrossRefGoogle Scholar
  65. 65.
    Schnell R et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma. Ann Oncol 2003; 14(5):729–36.PubMedCrossRefGoogle Scholar
  66. 66.
    Hartmann F et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin’s disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001; 7(7):1873–81.PubMedGoogle Scholar
  67. 67.
    Hartmann F et al. Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood 1997; 89(6):2042–7.PubMedGoogle Scholar
  68. 68.
    Borchmann P et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002; 100(9):3101–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Schnell R et al. Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23(21):4669–78.PubMedCrossRefGoogle Scholar
  70. 70.
    Hartmann F et al. Treatment of Hodgkin’s disease with bispecific antibodies. Ann Oncol 1996; 7Suppl 4:143–6.PubMedGoogle Scholar
  71. 71.
    Bartlett NL et al. Phase I study of SGN-30, a chimeric monoclonal antibody (mAB) in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2002; 100(11):Abs 1403.Google Scholar
  72. 72.
    Carabasi M et al. Pharmacokinetics, safety and tolerability of SGN-30, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies. Proc Am Soc Clin Oncol 2003; 22:Abs 722.Google Scholar
  73. 73.
    Bartlett NL et al. Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2003; 102(11):Abs 2390.Google Scholar
  74. 74.
    Leonard J et al. Phase II study to SGN-30 (Anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodgkin’s disease. Blood 2004; 104(11):Abs 2635.Google Scholar
  75. 75.
    Forero A et al. Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). J Proc Am Soc Clin Oncol 2005; 24: Abs 6601.Google Scholar
  76. 76.
    Schnell R, Borchmann P. SGN-30 (Seattle genetics). Curr Opin Mol Ther 2006; 8(2):164–72.PubMedGoogle Scholar
  77. 77.
    Shimozato O et al. Expression of CD30 ligand (CD153) on murine activated T-cells. Biochem Biophys Res Commun 1999; 256(3):519–26.PubMedCrossRefGoogle Scholar
  78. 78.
    Chakrabarty S et al. Critical roles of CD30/CD30L interactions in murine autoimmune diabetes. Clin Exp Immunol 2003; 133(3):318–25.PubMedCrossRefGoogle Scholar
  79. 79.
    Beckmann J et al. The role of CD30 in skin and heart allograft rejection in the mouse. Transplant Proc 2001; 33(1–2):140–1.PubMedCrossRefGoogle Scholar
  80. 80.
    Florido M et al. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium. J Leukoc Biol 2004; 76(5):1039–46.PubMedCrossRefGoogle Scholar
  81. 81.
    Blazar BR et al. CD30/CD30 ligand (CD153) interaction regulates CD4+ T-cell-mediated graft-versus-host disease J Immunol 2004; 173(5):2933–41.PubMedGoogle Scholar
  82. 82.
    Zeiser R et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T-cells in prevention of acute graft versus host disease. Blood 2006.Google Scholar
  83. 83.
    Polte T, Behrendt AK, Hansen G. Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol 2006; 118(4):942–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Lane PJ et al. CD4+CD3− cells regulate the organization of lymphoid tissue and T-cell memory for antibody responses. Int J Hematol 2006; 83(1):12–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006; 118(2):143–52.PubMedCrossRefGoogle Scholar
  86. 86.
    Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361(9352):151–60.PubMedCrossRefGoogle Scholar
  87. 87.
    Simpson EL, Hanifin JM. Atopic dermatitis. Med Clin North Am 2006; 90(1):149–67, ix.PubMedCrossRefGoogle Scholar
  88. 88.
    Folster-Holst R et al. Soluble CD30 plasma concentrations correlate with disease activity in patients with atopic dermatitis. Acta Derm Venereol, 2002; 82(4):245–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Caproni M et al. Soluble CD30 and cyclosporine in severe atopic dermatitis. Int Arch Allergy Immunol 2000; 121(4):324–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Bottari V et al. Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention. Allergy 1999; 54(5):507–10.PubMedCrossRefGoogle Scholar
  91. 91.
    Gerli R et al. Role of CD30+ T-cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001; 22(2):72–7.PubMedCrossRefGoogle Scholar
  92. 92.
    Okamoto A et al. Pathophysiological functions of CD30+CD4+ T-cells in rheumatoid arthritis. Acta Med Okayama 2003; 57(6):267–77.PubMedGoogle Scholar
  93. 93.
    Ciferska H et al. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol 2006.Google Scholar
  94. 94.
    Gerli R et al. CD30+ T-cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 200; 164(8):4399–407.Google Scholar
  95. 95.
    Oflazoglu E et al. CD30 expression on CD10a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. Eur J Dermatol. 2008; 18:41–49.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Ezogelin Oflazoglu
    • 1
  • Iqbal S. Grewal
    • 1
  • Hanspeter Gerber
    • 1
  1. 1.Department of Preclinical TherapeuticsSeattle Genetics, IncBothellUSA

Personalised recommendations